In recent years, great improvement has been made in immunotherapies for NSCLC, particularly monoclonal antibodies targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death-1(PD-1) and its ligand (PD-L1). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.